Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years old Accept VA-ECMO or VV-ECMO the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 50-70s. sign the informed consent form  Exclusion Criteria:  previous history of allergy to heparin or bivalirudin previous diagnosis of heparin-induced thrombocytopenia. the pre-random ECMO assistance time is more than 48 hours. pregnant female have participated in this study before. the researchers believe that there are other factors that are not suitable to participate in this study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult